Strategies for the design of hepatoselective glucokinase activators to treat type 2 diabetes

Glucokinase activators as potential antidiabetic agents possessing superior glucose lowering efficacies

(2015) M.C.T. Fyfe et al.   DRUGS OF THE FUTURE

Glucokinase Activators AZD6370 and AZD1656 Do Not Affect the Central Counterregulatory Response to Hypoglycemia in Healthy Males

(2012) Ensio Norjavaara et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Diabetes in numbers

(2012) Tony Scully   NATURE

The Expression and Function of Organic Anion Transporting Polypeptides in Normal Tissues and in Cancer

(2011) Amanda Obaidat et al.   Annual Review of Pharmacology and Toxicology

Effects of MK-0941, a Novel Glucokinase Activator, on Glycemic Control in Insulin-Treated Patients With Type 2 Diabetes

(2011) G. E. Meininger et al.   DIABETES CARE

Discovery of (S)-6-(3-Cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic Acid as a Hepatoselective Glucokinase Activator Clinical Candidate for Treating Type 2 Diabetes Mellitus

(2011) Jeffrey A. Pfefferkorn et al.   JOURNAL OF MEDICINAL CHEMISTRY

The Involvement of Organic Anion Transporting Polypeptide in the Hepatic Uptake of Telmisartan in Rats: PET Studies with [11C]Telmisartan

(2011) Tadayuki Takashima et al.   MOLECULAR PHARMACEUTICS

Designing glucokinase activators with reduced hypoglycemia risk: discovery of N,N-dimethyl-5-(2-methyl-6-((5-methylpyrazin-2-yl)-carbamoyl)benzofuran-4-yloxy)pyrimidine-2-carboxamide as a clinical candidate for the treatment of type 2 diabetes mellitus

(2011) Jeffrey A. Pfefferkorn et al.   MedChemComm

Discovery of novel hepatoselective HMG-CoA reductase inhibitors for treating hypercholesterolemia: A bench-to-bedside case study on tissue selective drug distribution

(2010) Jeffrey A. Pfefferkorn et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Novel glucokinase activators: a patent review (2008 – 2010)

(2010) Ramakanth Sarabu et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Glucokinase-activating GCKR Polymorphisms Increase Plasma Levels of Triglycerides and Free Fatty Acids, but do not Elevate Cardiovascular Risk in the Ludwigshafen Risk and Cardiovascular Health Study

(2010) D. H. Kozian et al.   HORMONE AND METABOLIC RESEARCH

Piragliatin (RO4389620), a Novel Glucokinase Activator, Lowers Plasma Glucose Both in the Postabsorptive State and after a Glucose Challenge in Patients with Type 2 Diabetes Mellitus: A Mechanistic Study

(2010) Riccardo C. Bonadonna et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Membrane transporters in drug development

(2010)   NATURE REVIEWS DRUG DISCOVERY

Modelling and PBPK Simulation in Drug Discovery

(2009) Hannah M. Jones et al.   AAPS Journal

The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver

(2009) Nicola L. Beer et al.   HUMAN MOLECULAR GENETICS

Investigation of Functionally Liver Selective Glucokinase Activators for the Treatment of Type 2 Diabetes

(2009) Gregory R. Bebernitz et al.   JOURNAL OF MEDICINAL CHEMISTRY

Assessing the potential of glucokinase activators in diabetes therapy

(2009) Franz M. Matschinsky   NATURE REVIEWS DRUG DISCOVERY

Glucokinase and molecular aspects of liver glycogen metabolism

(2008) Loranne Agius   BIOCHEMICAL JOURNAL

Molecular Physiology of Mammalian Glucokinase

(2008) P. B. Iynedjian   CELLULAR AND MOLECULAR LIFE SCIENCES

Restoration of Hepatic Glucokinase Expression Corrects Hepatic Glucose Flux and Normalizes Plasma Glucose in Zucker Diabetic Fatty Rats

(2008) T. P. Torres et al.   DIABETES

Glucokinase, the pancreatic glucose sensor, is not the gut glucose sensor

(2008) R. Murphy et al.   DIABETOLOGIA

New Drugs for Type 2 Diabetes Mellitus

(2008) Andrew J Krentz et al.   DRUGS

Glucokinase activators in diabetes management

(2008) Matthew Coghlan et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Discontinued drug in 2007: renal, endocrine and metabolic drugs

(2008) Jerry R Colca   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Glucokinase activators as new type 2 diabetes therapeutic agents

(2008) Ramakanth Sarabu et al.   EXPERT OPINION ON THERAPEUTIC PATENTS